Larimar Therapeutics, Inc. (LRMR)
|Net Income (ttm)||-42.48M|
|Trading Day||March 8|
|Day's Range||16.63 - 17.57|
|52-Week Range||0.62 - 25.87|
- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology...
Clinical-stage biopharma companies often face the risk of running out of cash reserves to fund their operations until they can push their investigational assets out of the clinics into the com...
Preliminary results from in vivo animal study not expected to warrant near-term resolution of clinical hold for ZGN-1061 Preliminary results from in vivo animal study not expected to warrant n...
Shares of Zafgen Inc (NASDAQ: ZFGN) were tumbling below the psychological barrier of $2 in Thursday's session.
The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug
Zafgem said it has planned to suspend to file an investigational new drug application, or IND, for its ZGN-1258, which it's evaluating for rare metabolic disorders including Prader-Willi syndr...
Larimar Therapeutics, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound is CTI-1601, a Phase 1 clinical program to treat Friedreich's ataxia, a rare and progressive genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.
Dr. Carole S. Ben-Maimon
|Stock Exchange |
|Ticker Symbol |